MARKET ACCESS

DOWNLOAD AGENDA

 

Access, Tuesday 19 March 2019

08:45

Organiser’s welcome Remarks

Opening Keynote Plenary

David Lane
09:00

Going global and keeping it local: Is biotech innovation sustainable in Asia?

In this keynote presentation, Sir David Lane, one of the key scientists credited on the discovery of cancer gene p53, a gene which mutation cause near 50% of all human cancer, will share his view on how biomedical sciences have developed in Singapore, Japan and the remaining APAC region, and prospects for Asian biotech and pharma industry.
Byung-Geon (BG) Rhee
09:20

Looking east: Integrating Asia into the global era of innovative medicine

Panel discussion
09:40

Pharma 4.0: Women health & Femtech as the next focus

Women’s health goes beyond mother & childcare. For instance, women has a higher risk of cardiovascular diseases compared to men, hence there is a need to invest more on addressing the biological differences in mainstream disease studies to ensure a more effective, personalised treatment. In addition, big data & AI application on female subjects may also differ from male subjects, prompting a need to investigate how studies should be developed differently in the future. This panel brings experts to debate and discuss how femtech is shaping to be the next global pharma focus and the new areas of focus in women's healthcare.
10:20

Speed networking & Networking Refreshment

PATIENT ACCESS

Access
11:15

Chair's opening remarks

Edmund Lim
Access
11:20

Starting from clinical phase: Patients involvement in building evidence and drug development (topic to be confirmed)

Nathan Kothandaraman
Access
11:40

The role of industry in facilitating low to mid income countries to build capabilities and healthcare accessibility

Panel discussion
12:40

Exhibition Visit & Networking Lunch

EVIDENCE BASED APPROACH

Access
14:10

Chair’s opening remarks

Philippe Pinton
Access
14:20

Maximizing RWE and PRO in Regulatory & reimbursement processes

Jun Feng
Access
14:40

Making a value-outcome-based reimbursement model possible: How do we get there?

Jun Feng, Market Access Associate Director - Oncology, JAPAC, Abbvie
Panel discussion
Access
15:00

RWE as the basis of value-based reimbursement: Applications in APAC’s pharma industry

  • Overview of data-driven reimbursement process in APAC
  • Overcoming barriers to increase use of real world data
  • Improving quality of real world data
  • Standardising access and quality of RWE analytics
  • Working with payors and regulators on possible value based reimbursement model for innovative drugs and beyond
15:40

Exhibition Visit & Networking Refreshments

VALUE & AFFORDABILITY

Susanne Weissbacker
Access
16:40

Sustainable patient access model to oncology & innovative medicines: A case study

Shailendra Bajpai
Access
17:00

Cost management & innovative pricing strategies in high value disease management (topic to be confirmed)

Dr Sushant Sahastrabuddhe
Access
17:20

Technology transfer and Product Development Partnerships (PDPs) in making vaccines affordable

17:40

Networking Cocktail & End of Conference Day 1

last published: 26/Sep/18 03:35

 

 

 

DOWNLOAD PROSPECTUS

 

 

For speaking, sponsorship and exhibition opportunities contact jonathan.mottram@terrapinn.com
Tel: +65 6322 2738